Keyword: Pharmaceutical Care Management Association
PBM tools such as rebates can help reduce drug costs for plans by nearly $1 trillion over the next decade, a PBM industry report said.
An oncologist group is pressing Congress to pass a 72-hour deadline for pharmacies, PBMs and insurers to approve and fill cancer drug prescriptions.
While Republicans are blasting Nancy Pelosi's drug plan as socialist, hospitals and insurers are finding a lot to like.
Healthcare experts weighed in on several House bills aimed at increasing transparency in the pharmaceutical supply chain at a hearing Tuesday.
Health insurers and pharmacy benefit managers aren't succeeding when it comes to drug access for autoimmune diseases, according to a new study.
The Trump administration’s plan to end legal protections for drug rebates would boost Part D premiums and federal spending, according to CBO.
Pharma CEOs went before the Senate last month, and now it’s PBMs’ turn to be on the hot seat.
PCMA released a statement calling HHS' proposed rule on prescription drug rebates for Medicare and Medicaid beneficiaries “poorly conceived."
Thanks to a bill introduced in Congress on Wednesday, drug rebates in commercial plans are on the chopping block.
The current structure of reimbursement for drugs in the U.S. is “regressive” and ultimately hurting patients, pharmaceutical executives said Tuesday.